Table 2. Genes implicated in cisplatin resistance and significantly differentially expressed in at least one pair of sensitive/resistant pancreatic cancer cell lines.

Gene	FC (AsPC1-R/S)	FC (BxPC3-R/S)	FC (BxPC3/AsPC1)	Mode of action in the resistance to cisplatin ref. (19, 20, 21, 22, 23, 24)
ABCC2	1.56a	NS	−12.92	Drug transport
ATP7A	NS	1.63a	−1.88	Drug transport
BCL2A1	NS	−2.08b	2.35	Apoptosis
BIRC3	2.42a	−4.46b	NS	Apoptosis
CCND1	1.51a	NS	NS	Cell cycle/apoptosis
CD44	1.72a	NS	1.95	Apoptosis
CFLAR	1.63a	−2.6b	NS	Apoptosis
CHEK2	NS	−1.55a	NS	DNA damage response
CLU	2.21a	2.75a	NS	Apoptosis
ERCC1	NS	1.63a	NS	Nucleotide excision repair
GCLC	1.9a	−2.2b	1.66	Drug inactivation
GCLM	2.23a	NS	3.88	Drug inactivation
GSTT2	1.55a	NS	NS	Drug inactivation
HIST1H1A	−2.07b	NS	3.96	Unknown
LRRFIP1	1.67a	2.01a	NS	Drug accumulation
MT2A	−2.96b	NS	8.50	Drug inactivation
MVP	NS	−1.94b	−1.61	Pleiotropic / drug transport
NQO1	NS	−1.76b	NS	Pleiotropic / ROS removal
POLB	1.72a	NS	NS	DNA translesion synthesis
SLC31A2	1.55a	NS	2.07	Drug transport

Abbreviations: NS, not significant; ROS, reactive oxygen species. FC(AsPC1-R/S), FC(BxPC3-R/S): Expression fold change between corresponding resistant/parental cells; FC(BxPC3/AsPC1): Expression fold change between two parental cell lines

^agene displays expression changes consistent with acquisition of resistant phenotype.

^bGene displays expression changes inconsistent with acquisition of resistant phenotype. Difference in the expression between parental cell lines is indicated in the 4th column ‘FC (BxPC3 vs AsPC1)'.